High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric β-lactamase assay

Indian Journal of Experimental Biology

Volumn 47, Issue 6 SPEC. ISS., 2009, Pages 475-479

  Mandal, Swati ^a   Maharjan, Mahendra ^a   Ganguly, Sudipto ^b   Chatterjee, Mitali ^b   Singh, Sarman ^c   Buckner, Frederick S ^d   Madhubala, Rentala ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

lactamase assay; Amastigotes; Drug screening; Indian clinical isolates; Leishmania donovani

Indexed keywords

LEISHMANIA DONOVANI; NASO HEXACANTHUS;

ANTIPROTOZOAL AGENT; BETA LACTAMASE;

ANIMAL; ARTICLE; BIOASSAY; CYTOLOGY; DRUG EFFECT; EVALUATION; GENETICS; HUMAN; LEISHMANIA DONOVANI; METABOLISM; METHODOLOGY; REPORTER GENE; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; BETA-LACTAMASES; BIOLOGICAL ASSAY; GENES, REPORTER; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL;

EID: 68249135710     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Desjeux P, The increase in risk factors for leishmaniasis worldwide, Trans R Soc Trop Med Hyg, 95 (2001) 239.
2. Bora D, Epidemiology of visceral leishmaniasis in India, Natl Med J India, 12 (1999) 62.
3. (Pubitemid 32299375) Sundar S, More D K, Singh M K, Singh V P, Sharma S, Makharia A, Kumar P C & Murray H W, Failure of pentavalent antimony in visceral leishmaniasis in India: report from the centre of the Indian epidemic, Clin Infect Dis 31 (2000) 1104.
4. Thakur C P & Kumar K, Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes, Ann Trop Med Parasitol, 86 (1992) 355.
5. Zijlstra E E, Musa A M & Khalil E A, Post-kala-azar dermal leishmaniasis, Lancet Infect Dis, 3 (2003) 87.
6. Herwaldt B L, Leishmaniasis, Lancet, 354 (1999) 1191.
7. Wolday D, Berhe N, Akuffo H & Britton S, Leishmania-HIV interaction: Immunopathogeneic mechanism, Parasitology Today, 15 (1999) 182.
8. Ivens A C, Peacock C S, Worthey E A, Murphy L, Aggarwal G, Berriman M, Sisk E, Rajandream M A, Adlem E, Aert R, Anupama A, Apostolou Z, Attipoe P, Bason N, Bauser C, Beck A, Beverley S M et al., The genome of the kinetoplastid parasite, Leishmania major, Science, 309 (2005) 436.
9. Buckner F S, Verlinde C L M J, La Flamme A C & Van Voorhis W C, Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase, Antimicrob Agents Chemother, 40 (1996) 2592.
10. Monte-Alegre A, Ouaissi A & Sereno D, Leishmania amastigotes as targets for drug screening, Kinetoplastid Biol Dis, 5 (2006) 6.
11. Buckner F S & Wilson A J, Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages, Am J Trop Med Hyg, 72 (2005) 600.
12. Roy G, Dumas C, Sereno D, Wu Y, Singh A K, Tremblay M J, Ouellette M, Olivier M & Papadopoulou B, Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models, Mol Biochem Parasitol, 110 (2000) 195.
13. (Pubitemid 47072058) Mukherjee A, Padmanabhan P K, Singh S, Roy G, Girard I, Chatterjee M, Ouellette M & Madhubala R, Role of ABC transporter MRPA, γ-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani, J Antimicrob Chemother, 59 (2007) 204.
14. Jones R N, Wilson H W, Novick Jr W J, Barry A L & Thornsberry C, In vitro evaluation of CENTA, a new bet al.actamase-susceptible chromogenic cephalosporin reagent, J Clin Microbio, 15 (1982) 954.
15. (Pubitemid 32299377) Sundar S, Makharia A, More D K, Agrawal G, Voss A, Fischer C, Bachmann P & Henry W, Short-course of oral miltefosine for treatment of visceral leishmaniasis, Clin Infect Dis, 31 (2000) 1110.
16. Sundar S, Treatment of visceral Leishmaniasis, Med Microbiol Immunol, 190 (2001) 89.
17. Thakur C P, Kanyok T P & Pandey A K, Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study, Trans RSoc Trop Med Hyg, 94 (2000) 432.
18. Thakur C P, Kumar A, Mitra G, Thakur S, Sinha P K, Das P, Bhattacharya S K & Sinha A, Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India, Indian J Med Res 128 (2008) 38.
19. (Pubitemid 29313533) Aggarwal P, Handa R, Singh S & Wali J P, Kala-azar: new development in diagnosis and treatment, Indian J Pediat, 66 (1999) 63.